Verastem Oncology has unveiled updated early-stage data from its RAMP 205 trial in metastatic pancreatic cancer, bolstering ...

Tempus AI is expanding its partnership with Verastem Oncology to develop a companion diagnostic (CDx) for the latter’s ...

2025--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced ...

The most notable development for Verastem has been the U.S. Food and Drug Administration (FDA) approval of its drug Avmapki Fakzynja Co-Pack (Av-Fak) for the treatment of low-grade serous ovarian ...

Tempus completed confirmatory testing in Verastem’s Phase 2 RAMP-201 clinical trial, which evaluated the combination of avutometinib and defactinib to treat recurrent low-grade serous ovarian ...

VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Advanced Solid Tumors To supplement Verastem Oncology’s condensed consolidated financial statements, which are prepared and presented in ...

The Needham, Massachusetts-based company said it had a loss of 96 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic ...

In April 2025, Verastem strengthened its balance sheet by raising gross proceeds of approximately $75 million in a private placement of 3.4 million shares of its common stock and 7.3 million pre ...

NEEDHAM, Mass. (AP) — NEEDHAM, Mass. (AP) — Verastem Inc. (VSTM) on Tuesday reported a loss of $52.1 million in its first quarter. The Needham, Massachusetts-based company said it had a loss ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...